Medications and conditions associated with weight loss in patients prescribed semaglutide based on real-world data.

ABSTRACT:

Objective

Approved by the Food and Drug Administration (FDA) in 2017 for diabetes and in 2021 for weight loss, semaglutide has seen widespread use among individuals who aim to lose weight. The aim of this study was to evaluate weight loss and the influence of clinical factors on semaglutide patients in real-world clinical practice.

Methods

Using data from 10 health systems within the Greater Plains Collaborative (a PCORnet Clinical Research Network), nearly 4000 clinical factors encompassing demographic, diagnosis, and prescription information were extracted for semaglutide patients. A gradient-boosting, machine-learning classifier was developed for weight-loss prediction and identification of the most impactful factors via SHapley Additive exPlanations (SHAP) value extrapol

SUBMITTER: Powell W 

PROVIDER: S-EPMC10702395 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature